

California State University, Fresno
Department of Biology Colloquium Seminar Series
presents

Steven Miller, PhD

Associate Director of Corporate Strategy
and Business Development,
Marinus Pharmaceuticals



“Pharmaceutical Careers for Science Degrees: Focus on Medical Affairs and Business Development”

Steven Miller began his research career by volunteering in the cancer proteomics lab of Dr. Jason Bush at CSU Fresno. He eventually graduated from Fresno State with a BS in Biology with an option in anatomy and physiology and a minor in chemistry. During physiology coursework he became very interested in the neurosciences and subsequently moved to Washington DC to pursue a PhD in neuroscience.

Steven obtained his PhD from the lab of Dr. Maria Braga at Uniformed Services University and was trained primarily in electrophysiology and neuropharmacology of seizure disorders. Work for his dissertation included developing a juvenile rodent model of chemical weapon-induced seizures & status epilepticus and focused on potential mechanisms of seizure initiation, as well as testing the ability of novel anticonvulsants to arrest these seizures.

After his PhD work, he completed a postdoctoral fellowship in the lab of Dr. Hermes Yeh at Dartmouth Medical School. Work at Dartmouth focused on understanding the electrophysiological mechanisms of fetal alcohol spectrum disorders and the potential overlap with epilepsy in severe cases of fetal alcohol syndrome.

Following his work in academia he decided to pursue a career in the pharmaceutical industry and has focused solely on developing new drugs for rare and severe pediatric-onset epilepsies. His first industry role was in the Medical Affairs division of GW Pharmaceuticals where he helped launch Epidiolex, the first cannabis-derived drug approved by the FDA, for the treatment of seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex. He is now at Marinus Pharmaceuticals where he is the Associate Director of Corporate Strategy and Business Development, and is helping the company develop the neurosteroid, ganaxolone, as a novel anticonvulsant for chronic and acute treatment of several different seizure disorders.

Friday, Oct. 15, 2021, 3:00 – 4:00 pm

<https://fresnostate.zoom.us/j/85974417523?pwd=WTBXTJMaWpMc0Z6bW02Q3dhY0tQZz09>

Meeting ID: 859 7441 7523 Passcode: 828325

In case the link did not work you are welcome to use the meeting ID# above to join us

If you need a disability-related accommodation, please contact Lindasue Garner at the Department of Biology at 278-2001 or e-mail lgarner@csufresno.edu (at least one week prior to event).